Targeting DNA replication in breast cancer linked to BRCA mutations
Project 2: Targeting DNA replication in BRCA-associated breast cancer
['FUNDING_P01'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-11080259
This study is looking at how changes in the BRCA1 and BRCA2 genes affect the way breast cancer cells copy their DNA, especially when the DNA is damaged, to help find new treatment options for patients with BRCA-related breast cancer.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-11080259 on ClinicalTrials.gov |
What this research studies
This research investigates how mutations in the BRCA1 and BRCA2 genes affect DNA replication in breast cancer cells. It focuses on understanding the mechanisms by which these genes regulate DNA synthesis, especially after DNA damage. The study aims to explore the interactions between BRCA proteins and other factors involved in DNA replication, which could lead to insights into cancer progression and treatment. By examining how these mutations impact replication fidelity and genome stability, the research seeks to identify potential therapeutic targets for patients with BRCA-associated breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer who carry BRCA1 or BRCA2 mutations.
Not a fit: Patients without BRCA mutations or those with other types of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for breast cancer patients with BRCA mutations by targeting specific mechanisms of DNA replication.
How similar studies have performed: Other research has shown promising results in targeting DNA repair mechanisms in cancer, suggesting that this approach could be effective.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XIA, BING — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: XIA, BING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy